OAM
ADMA icon

Oberweis Asset Management’s ADMA Biologics ADMA Stock Holding History

Oberweis Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,712,040
Closed -$39.8M – 179
2025
Q3 		$39.8M Sell
2,712,040
-423,850
-14% -$7.27M 1.52% 9
2025
Q2 		$57.1M Sell
3,135,890
-290,370
-8% -$5.92M 2.48% 2
2025
Q1 		$68M Buy
3,426,260
+83,700
+3% +$1.45M 3.39% 1
2024
Q4 		$57.3M Buy
3,342,560
+435,480
+15% +$8.19M 2.7% 2
2024
Q3 		$58.1M Buy
2,907,080
+866,380
+42% +$13.5M 2.98% 1
2024
Q2 		$22.8M Sell
2,040,700
-750,000
-27% -$6.29M 1.4% 11
2024
Q1 		$18.4M Buy
2,790,700
+80,000
+3% +$437K 1.33% 7
2023
Q4 		$12.3M Buy
2,710,700
+632,300
+30% +$2.34M 1.14% 12
2023
Q3 		$7.44M Buy
2,078,400
+409,700
+25% +$1.58M 0.79% 24
2023
Q2 		$6.16M Buy
1,668,700
+499,200
+43% +$1.85M 0.75% 32
2023
Q1 		$3.87M Buy
1,169,500
+632,600
+118% +$2.19M 0.6% 37
2022
Q4 		$2.08M Buy
+536,900
New +$1.66M 0.44% 68

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Oberweis Asset Management's ADMA Position: Q4 2025 in Review

Oberweis Asset Management sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 2,712,040 shares — an estimated $39.8M sold.

Oberweis Asset Management first reported a position in ADMA in Q4 2022 and held it in 12 quarters. The position peaked at $68M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • Oberweis Asset Management reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • Oberweis Asset Management sold 2,712,040 ADMA Biologics shares in Q4 2025, an estimated $39.8M.
  • Oberweis Asset Management first reported a position in ADMA Biologics in Q4 2022 and held it in 12 quarters.
  • Oberweis Asset Management's ADMA Biologics position peaked at $68M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Oberweis Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.